Aims: Our aim was to assess the incidence of aortic regurgitation (AR) after transcatheter aortic valve implantation (TAVI) with the second (SXT) versus third-generation (S3) balloon-expandable SAPIEN prosthesis in patients with symptomatic aortic stenosis (AS).
Introduction
With the increasing experience of operators complemented by improvement in prosthetic valve platforms, percutaneous transcatheter aortic valve implantation (TAVI) is becoming a frequently used treatment option not only for patients deemed unsuitable or at high risk for surgical repair but also for elderly patients at intermediate operative risk 1, 2 . Nevertheless, with the first and secondgeneration TAVI prostheses, aortic regurgitation (AR) is more frequently observed than after surgical valve repair. The use of balloon-expandable aortic valve prostheses has been proven superior to self-expandable TAVI prostheses in terms of the incidence of device success, post-TAVI AR and the need for new pacemaker implantation [3] [4] [5] [6] . Among the aforementioned adverse events, post-TAVI more-than-mild AR has been identified as an independent predictor of short and long-term mortality 5, [7] [8] [9] . The SAPIEN 3 prosthesis (S3; Edwards Lifesciences Inc., Irvine, CA, USA) is the latest revision of the balloon-expandable aortic valve prostheses targeting reduction of post-TAVI paravalvular leak. Different from the second-generation SAPIEN XT prosthesis (SXT), the S3 consists of a novel steerable balloon system allowing accurate positioning of the valve in the native annulus, a new cobalt-chromium frame with large cell design containing the valve and an outer polyethylene terephthalate cuff to enhance paravalvular sealing 8 . Recent studies including a modest number of patients have demonstrated promising data regarding the acute clinical performance of the S3, reporting a post-TAVI more-than-mild AR rate of about 2-4% 10 .
To assess and compare differences in performance between the newer S3 prosthesis and the second-generation SXT prosthesis with regard to post-TAVI AR, we analysed the outcomes of all consecutive patients with symptomatic aortic valve stenosis undergoing transfemoral balloon-expandable prosthesis implantation in our centre.
Material and methods

PATIENTS
Between May 2010 and July 2014, of a total of 634 patients with symptomatic aortic stenosis who underwent transfemoral TAVI procedures at the Munich University Clinic, Munich, Germany, 454 received a balloon-expandable prosthesis and were included in this study. From May 2010 to December 2013, 354 patients underwent SXT implantation (78.0%), while, from January 2014 to July 2014, 100 patients underwent S3 implantation (22.0%). Demographics, clinical and procedural data as well as echocardiographic data were prospectively documented in the dedicated database of our institution as part of national quality control requirements. Thirty-day clinical follow-up was available for all patients and was performed either by phone or at the outpatients clinic.
PRE-TAVI ASSESSMENT
All patients planned for TAVI procedure were assessed by transthoracic echocardiography and in a minority of cases transoesophageal echocardiography. A multi-detector row CT (MDCT) scan was performed in 85% of the population (n=388) to evaluate the diameter and anatomy of the aortic ring and the aortic valve complex, as well as the vessels for access site, as part of our clinical routine. For patients with severe coronary artery disease, percutaneous coronary intervention was performed prior to TAVI. Evaluation of aortic valve calcification was done semi-quantitatively as previously described 3 . Suitability of patients for TAVI was evaluated within the Heart Team including experienced clinical and interventional cardiologists, cardiovascular surgeons and anaesthesiologists. 3, 8 . TAVI procedures were mainly performed under local anaesthesia via the transfemoral access. The decision to perform pre-or post-dilation was left to the operator. The decision regarding the prosthesis size was based on the area of the native annulus or the effective diameter in case only echocardiography was available, aiming to achieve an oversize of 10%-15% with SXT prosthesis and 10% with S3 prosthesis. Antithrombotic therapy consisted of unfractionated heparin 50-70 IU/kg of body weight or bivalirudin, clopidogrel as a loading dose of 300-600 mg and 75 mg/daily for three months, as well as 100 mg aspirin lifelong. If oral anticoagulation was indicated, it was continued after TAVI as monotherapy.
DEVICE AND PROCEDURE DESCRIPTION
DEFINITIONS AND OUTCOMES OF INTEREST
The primary outcome of interest was the incidence of more-thanmild post-TAVI AR determined by echocardiography at hospital discharge. Secondary outcomes of interest were bleeding complications, need for new pacemaker and all-cause mortality at 30-day follow-up. Post-TAVI AR was assessed after procedural implantation at the catheterisation laboratory by using supravalvular angiography after withdrawal of the delivery guidewire from the left ventricle. Aortographies in the 30° right anterior oblique projection and the 40° left anterior oblique projection were recorded over several cardiac cycles. The amount of contrast media used ranged between 25-30 ml injected with a flow rate of 15 ml/sec. The severity of post-TAVI AR was assessed visually by two experienced operators using the method of Sellers et al 11 and classified as: none-trace (0), mild (1/3), moderate (2/3) and severe (3/3). Transthoracic Doppler echocardiography examinations were performed prospectively by two experienced physicians, and in challenging cases a third one repeated the examination and took the final decision. The severity of post-TAVI AR was assessed semi-quantitatively by estimating the proportion of the circumference of the prosthesis covered by the AR jet measured at the short-axis view: less than 10% was graded as mild, 10% to 29% as moderate, and ≥30% as severe paravalvular aortic regurgitation. Device success and other endpoints were defined according to the current VARC-2 consensus 12 .
Statistical analysis
The population was divided into two groups according to the implanted prosthesis type, S3 and SXT. Continuous data are presented as mean (standard deviation). Categorical data are presented as counts or proportions (%). Data distribution was tested for normality using the Kolmogorov-Smirnov test for goodness of fit. Differences between groups were checked for significance using the Student's t-test or Wilcoxon rank-sum test (continuous data) or the chi-square or Fisher's exact test where the expected cell value was <5 (categorical variables). Odds ratios, confidence intervals and p-values were calculated by means of logistic regression analysis using any post-TAVI AR by echocardiography as dependent variable. Multivariable analysis included risk variables that showed a statistical association with the dependent variable (p-value ≤0.10). Missing data in any of the variables considered in the multivariable analysis were neglected. A two-tailed p-value of <0.05 was considered to indicate statistical significance. Statistical software R-Statistics (version 3.1.0) was used for analysis.
Results
BASELINE CHARACTERISTICS AND PROCEDURAL DETAILS
Detailed information regarding baseline and procedural characteristics is provided in Table 1 . No differences were observed between S3 and SXT-treated patients except for the EuroSCORE II, NYHA Class ≥II, incidence of malignancies, mean procedure time and pre/ post-dilation frequency. As shown in Table 2 , no differences were observed in baseline echocardiographic and MDCT parameters except for the proportion of patients with reduced LV function, the effective annulus diameter, area cover index, degree of severe aortic cusp calcification and the diameter of the common femoral artery.
PROCEDURAL COMPLICATIONS AND 30-DAY CLINICAL OUTCOMES
Regarding the peri-TAVI complications, no differences were observed between both groups except a higher incidence of new conduction abnormalities in the S3 group (Table 3) . The incidence of the primary outcome of interest, more-than-mild post-TAVI AR by echocardiography at discharge, was observed less frequently after implantation of the S3 prosthesis compared to the SXT (2.0% vs. 8.8%, p<0.01) which was also confirmed by angiography (Figure 1) . In the multivariable analysis, an independent Table 4 ). Furthermore, we analysed the incidence and severity of post-TAVI AR in subgroups with 50 patients each to evaluate the possible impact of the operators' learning curve on this event. After the first 100 SXT implantation procedures, the rate of more-than-mild AR was reduced; however, it still remained higher compared to the incidence of AR post S3 implantation (Figure 3) . Thirty-day follow-up was available for all patients. In total, 16 patients died (3.5%), without significant difference in both groups (p=0.13). Compared to the SXT-treated group, in the S3-treated group the rate of bleeding complications was significantly lower, while the need for new pacemaker and the proportion of patients with new left bundle branch block at discharge were significantly higher (Table 3) . 
30-day clinical outcomes according to VARC-2 criteria
Discussion
Our study is the largest single-centre experience with second and third-generation balloon-expandable prostheses in patients undergoing TAVI. The main findings of this analysis are: i) the use of the third-generation balloon-expandable S3 prosthesis is associated with a substantially lower incidence of both any and morethan-mild post-TAVI AR compared to the second-generation SXT prosthesis; ii) the type of prosthesis implanted is identified as the only independent predictor of post-TAVI AR; iii) compared to the SXT prosthesis, clinical outcomes, particularly bleeding risk, are improved after implantation of the S3 prosthesis while the incidence of new conduction disturbances is increased. Post-TAVI AR remains a major limitation of earlier-generation TAVI prostheses and is mainly provoked by several causes related to valve positioning and sizing 5, 13 , annular anatomy, including presence and distribution of calcium 14, 15 , and notably the type of prosthesis 3, 5 . The incidence of more-than-mild post-TAVI AR after SXT implantation in our study was 8.8%, which is within the reported range of 3% to 13% in the current literature 3, 5, 7 . In addition, the observed rate of any post-TAVI AR of 60% is also within the range of 40%-70% reported with the SXT prosthesis in other studies 3, 6, 10 . The third generation of balloon-expandable S3 prosthesis is designed to target post-TAVI paravalvular leak. Recent studies including a modest number of patients have demonstrated promising data regarding acute clinical performance of S3, reporting, similar to our series (2%), a post-TAVI more-thanmild AR rate up to 4% 10 . Post-TAVI AR mostly originates from incomplete apposition of the aortic valve frame against the native wall 16 . While undersizing can lead to severe paravalvular AR, excessive oversizing may induce annulus rupture 13, 17 . Our data show that improvement in S3 prosthesis design allows for less oversize to achieve less post-TAVI AR compared to SXT (9% vs. 14.8%). Another important factor that might improve prosthesis haemodynamics is balloon post-dilatation. The rationale to perform post-dilation is either the incomplete delivery of pressure to the balloon or the incomplete expansion of the valve prosthesis due to intense resistance of the aortic wall 18 . Post-dilatation in some cases reduces post-TAVI AR, but on the other hand it also increases the risk of neurological events and aortic trauma 17, 18 . The need for post-dilation is substantially reduced after implantation of the S3 10 (9% vs. 31% in the SXT group) which is partially contributed to by the substantial reduction of procedural time with the S3 prosthesis.
Aortic valve calcification is essential to anchor and achieve appropriate positioning of a balloon-expandable TAVI prosthesis.
On the other hand, severe and asymmetric distribution of calcium masses has been associated with post-TAVI paravalvular AR 14, 19 . In our study, a severe degree of aortic valve calcification did not predict the risk of post-TAVI AR.
More-than-mild AR after implantation of earlier generations of balloon-expandable prostheses has been associated with increased mortality 9, 20, 21 . Similar to other studies, 30-day mortality among SXT-treated patients in our study was 4.2%, which is numerically higher than the mortality among S3-treated patients (1.0%, p=0.13). Caution is required in interpreting these findings. First, the number of S3-treated patients is still modest for evaluating mortality. Second, compared to SXT-treated patients, S3-treated patients presented with a lower EuroSCORE II -which might reflect changes in indication for TAVI in time -and also significantly less frequently experienced bleeding complications which might have positively influenced survival after TAVI. Third, a greater impact of the operators' learning curve on the outcomes of the SXT prosthesis (S3 was used after 3.5 years of experience with SXT) cannot be ruled out.
A novel observation of our study is the twofold increase in the rate of new conduction disturbances with the S3 prosthesis compared to the SXT prosthesis, although similar rates of new pacemaker implantation were observed. Assessment of factors determining this complication is beyond the scope of this paper. However, it can be speculated that the higher proportion of severely calcified aortic valves among S3-treated patients as well as the S3 novel frame with larger angles between struts and interwoven rows of cells designed for high radial strength to achieve optimal circularity might increase the rate of conduction disturbances. The higher pacemaker rate reported after implantation of other novel prostheses with higher radial strength, such as the Lotus™ (Boston Scientific, Marlborough, MA, USA), supports this hypothesis 22 . Despite this, our findings strongly suggest reduction of limiting and life-threatening complications of TAVI procedures with the new S3 prosthesis.
Limitations
First, the present study is a non-randomised comparison of two different generations of balloon-expandable prostheses. Second, although the reduction of post-TAVI AR with the S3 evaluated by echocardiography was confirmed angiographically, a central echocardiographic core laboratory evaluation was not performed. Furthermore, the sample size is enough for the kind of analysis performed but insufficient to unveil rare complications and clinical outcomes.
Conclusions
In patients undergoing transfemoral aortic valve implantation, the third-generation balloon-expandable S3 prosthesis substantially reduces post-TAVI aortic regurgitation compared to the second-generation SXT. Its use independently predicts lower post-TAVI AR risk and is associated with better clinical outcomes.
Impact on daily practice
Aortic regurgitation after transcatheter aortic valve implantation (TAVI) has been shown to increase long-term mortality. Therefore, improvements in prosthesis design are targeted towards this complication. In our study, compared to the earliergeneration balloon-expandable SAPIEN XT prosthesis, the use of the new revision SAPIEN 3 is associated with a significant reduction of post-TAVI aortic regurgitation, which is independent of other known risk factors. Furthermore, periprocedural and 30-day clinical outcomes seem to be better with the S3 compared to the SXT prosthesis, suggesting a better overall performance of the new S3 prosthesis in everyday practice.
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